Molecular Partners AG (MOLN)
3.72
-0.16
(-4.12%)
USD |
NASDAQ |
Jun 10, 16:00
3.72
0.00 (0.00%)
After-Hours: 18:04
Molecular Partners Enterprise Value : 51.68M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 51.68M |
| June 08, 2026 | 54.31M |
| June 05, 2026 | 59.93M |
| June 04, 2026 | 53.56M |
| June 03, 2026 | 57.31M |
| June 02, 2026 | 53.18M |
| June 01, 2026 | 54.31M |
| May 29, 2026 | 63.68M |
| May 28, 2026 | 56.29M |
| May 27, 2026 | 57.68M |
| May 26, 2026 | 58.06M |
| May 22, 2026 | 62.93M |
| May 21, 2026 | 48.68M |
| May 20, 2026 | 46.43M |
| May 19, 2026 | 46.43M |
| May 18, 2026 | 48.68M |
| May 15, 2026 | 50.18M |
| May 14, 2026 | 50.18M |
| May 13, 2026 | 56.18M |
| May 12, 2026 | 57.69M |
| May 11, 2026 | 61.06M |
| May 08, 2026 | 59.93M |
| May 07, 2026 | 59.93M |
| May 06, 2026 | 66.89M |
| May 05, 2026 | 65.56M |
| Date | Value |
|---|---|
| May 04, 2026 | 71.43M |
| May 01, 2026 | 65.18M |
| April 30, 2026 | 64.81M |
| April 29, 2026 | 73.06M |
| April 28, 2026 | 66.68M |
| April 27, 2026 | 69.31M |
| April 24, 2026 | 73.43M |
| April 23, 2026 | 71.19M |
| April 22, 2026 | 68.94M |
| April 21, 2026 | 69.31M |
| April 20, 2026 | 71.56M |
| April 17, 2026 | 63.87M |
| April 16, 2026 | 62.93M |
| April 15, 2026 | 63.68M |
| April 14, 2026 | 61.43M |
| April 13, 2026 | 64.05M |
| April 10, 2026 | 68.64M |
| April 09, 2026 | 68.64M |
| April 08, 2026 | 65.18M |
| April 07, 2026 | 51.30M |
| April 06, 2026 | 57.68M |
| April 02, 2026 | 50.56M |
| April 01, 2026 | 56.37M |
| March 31, 2026 | 55.02M |
| March 30, 2026 | 34.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kuros Biosciences Ltd. | 6.511M |
| BeOne Medicines Ltd. | 24.64B |
| AC Immune SA | 142.21M |
| CRISPR Therapeutics AG | 3.307B |
| Idorsia Ltd. | 2.960B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.77M |
| Total Expenses (Quarterly) | 16.77M |
| EPS Diluted (Quarterly) | -0.4472 |
| Earnings Yield | -51.76% |
| Normalized Earnings Yield | -50.12 |